Advertisement

Topics

EC approves expanded use of Novartis’ lung cancer treatment Zykadi

02:05 EDT 30 Jun 2017 | Pharmaceutical Business Review

Novartis has secured approval from the European Commission (EC) for Zykadi to serve as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.

Original Article: EC approves expanded use of Novartis’ lung cancer treatment Zykadi

NEXT ARTICLE

More From BioPortfolio on "EC approves expanded use of Novartis’ lung cancer treatment Zykadi"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...